問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Obstetrics & Gynecology

Division of Radiation Therapy

Division of Hematology & Oncology

Digestive System Department

更新時間：2023-09-19

賴冠銘
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

53Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

賴冠銘

List

100Cases

2016-12-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double Blind, Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Venetoclax (ABT-199)

Participate Sites
6Sites

Terminated5Sites

蕭樑材
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-08-01 - 2023-05-31

Phase III

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Venetoclax (ABT-199/GDC-0199)

Participate Sites
5Sites

Terminated4Sites

2014-07-01 - 2020-12-31

Phase III

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients

  • Condition/Disease

    Advanced Nasopharyngeal Carcinoma

  • Test Drug

    Epstein-Barr virus-specific autologous cytotoxic T lymphocytes

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

謝清昀
China Medical University Hospital-Taipei

未分科

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2015-09-01 - 2021-01-31

Phase III

A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma

  • Condition/Disease

    Low Tumour Burden Follicular Lymphoma

  • Test Drug

    CT-P10

Participate Sites
5Sites

Terminated5Sites

2021-02-26 - 2023-10-24

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2022-03-31 - 2023-09-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Terminated2Sites

2017-12-01 - 2020-12-31

Phase III

GRAVITAS-301： A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

  • Condition/Disease

    Acute Graft Versus Host Disease

  • Test Drug

    Itacitinib

Participate Sites
4Sites

Terminated3Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2019-01-22 - 2022-07-12

Phase III

A Randomized, Double-blind, Active-controlled, Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ABP 959

Participate Sites
3Sites

Recruiting3Sites

2016-09-08 - 2019-10-31

Phase III

A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Vadastuximab Talirine

Participate Sites
4Sites

Terminated4Sites

蕭樑材
Taipei Veterans General Hospital

1 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB